Clinical Trials (Phase I)
Filter News
Found 15,194 articles
-
AVEO Oncology Announces Results from Phase 1b Portion of DEDUCTIVE Study of Tivozanib (FOTIVDA®) in Combination with IMFINZI® (durvalumab) in Previously Untreated Metastatic Hepatocellular Carcinoma
1/15/2021
AVEO Oncology (Nasdaq: AVEO) today announced the presentation of results from the Phase 1b portion of the Phase 1b/2 DEDUCTIVE clinical trial of tivozanib (FOTIVDA®), AVEO’s vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI) drug candidate, in combination with IMFINZI® (durvalumab),
-
Arcus Biosciences Presents Promising Initial Data from Phase 1 Portion of ARC-8 Study for AB680 in Metastatic Pancreatic Cancer
1/15/2021
Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today presented preliminary data from the dose-escalation portion of its ARC-8 Phase 1/1b study, evaluating the safety and tolerability of AB680, the first small-molecule CD73 inhibitor to enter the clinic, in metastatic pancreatic cancer at the ASCO 2021 Virtual Gastrointestinal Cancers Symposium (ASCO GI).
-
Senhwa Biosciences Presents Positive Cholangiocarcinoma Data
1/15/2021
Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company focused on next generation DNA Damage Response (DDR) therapeutics for the treatment of cancer, today announces that promising clinical data from their global phase 1b/2 trial, evaluating the combination of Silmitasertib plus Gemcitabine and Cisplatin
-
Johnson & Johnson published interim Phase I/IIa data in the New England Journal of Medicine showing its single-dose COVID-19 vaccine candidate created an immune response that lasted at least 71 days.
-
aTyr Pharma Announces Partner Kyorin Pharmaceutical, Co., Ltd. Completes Subject Visits for Phase 1 Trial of ATYR1923 in Japan
1/14/2021
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that its partner Kyorin Pharmaceutical Co., Ltd., or Kyorin, a wholly owned subsidiary of Kyorin Holdings, Inc., has completed the last subject visit in its Phase 1 clinical trial of aTyr’s lead therapeutic candidate ATYR1923 (known as KRP-R120 in Japan).
-
Ampio Pharmaceuticals Ongoing Phase I Clinical Trial for Inhalation Treatment of COVID-19 with Ampion is 55% Enrolled
1/14/2021
Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced its ongoing U.S. Phase I clinical trial for inhalation treatment of COVID-19 with Ampion (AP-014) is 55% enrolled.
-
Adastra Pharmaceuticals’ positive results from a Phase Ib trial of its therapy for recurrent high-grade glioblastomas suggest an effective treatment could be available within the next several years.
-
Jounce Therapeutics Announces Initiation of Phase 1 INNATE Study of JTX-8064 (LILRB2/ILT4 Inhibitor) Monotherapy and PD-1 Inhibitor Combination Therapy in Patients with Advanced Solid Tumors
1/13/2021
- INNATE is a robust Phase 1 study designed to dose escalate quickly and demonstrate proof of concept for JTX-8064 monotherapy and PD-1i combinations - - Tumor-specific expansion cohorts to include PD-(L)1i resistant and sensitive tumors and PD-(L)1i naïve and experienced patients -
-
Adastra Pharmaceuticals Announces Positive Top-Line Data from Phase 1b Clinical Trial of Zotiraciclib in the Treatment of Recurrent High-grade Gliomas
1/13/2021
- National Cancer Institute (NCI) study investigating zotiraciclib (ZTR) in combination with temozolomide (TMZ) demonstrates meaningful clinical efficacy - ZTR has a favorable safety profile and was found to be well tolerated - Based on positive top-line Phase 1b data, Adastra Pharmaceuticals, Inc. is steadfast in undertaking a registration-enabling clinical study in the first half of 2021
-
China NMPA Grants Approval for the Registrational Phase 1/2 Clinical Study for GC007g - an Allogeneic CAR-T Cell Therapy for the Treatment of Relapsed or Refractory B-ALL
1/13/2021
Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, has been granted approval for a pivotal seamless Phase 1/2 clinical trial for GC007g, an allogeneic donor-derived anti-CD19 chimeric antigen receptor (CAR)-T cell therapy,
-
The novel immune checkpoint inhibitor Sanofi deemed worthy of such an investment is BND-22, a humanized IgG4 antagonist antibody targeting the Ig-like transcript 2 (ILT2) receptor, an inhibitory receptor expressed on both innate and adaptive immune cells.
-
While Sutro’s technological platform opens multiple therapeutic doors, the company’s singular focus on homogeneous molecules is a key part of its competitive strategy.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for January 12, 2021.
-
Gannex Announces Positive Phase I Clinical Results on Its THR-β Agonist ASC41
1/12/2021
Gannex, a wholly owned company of Ascletis Pharma Inc. (HKEX: 1672) and fully dedicated to the R&D and commercialization of new drugs in the field of non-alcoholic steatohepatitis (NASH), today announces the positive phase I clinical results of ASC41
-
Clearside Biomedical Announces First Patients Enrolled in Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) for the Treatment of Wet AMD
1/12/2021
Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that the first patients have been enrolled in its Phase 1/2a clinical trial of CLS-AX (axitinib injectable suspension) in patients with neovascular age-related macular degeneration (wet AMD). Clinical sites, all based in the Uni
-
Veralox Therapeutics Announces IND Submission for VLX-1005 to Treat Heparin-Inducted Thrombocytopenia
1/12/2021
Veralox Therapeutics, today announced it submitted an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for initiation of a Phase 1 clinical trial of VLX-1005, a first-in-class small molecule inhibitor of 12-Lipoxygenase in development for the treatment of heparin-induced thrombocytopenia (HIT).
-
New Treatment for Central Nervous System Tumors Enters Phase I Clinical Trials
1/12/2021
n, a privately held Minneapolis company, announces that they treated their first patient in a phase one human trial of a new treatment developed to combat recurrent high-grade brain tumors.
-
Rezolute Announces Initiation of Phase 1 Study of RZ402, an Oral Plasma Kallikrein Inhibitor for the Treatment of Diabetic Macular Edema
1/12/2021
Rezolute, Inc. (Nasdaq: RZLT), today announced the initiation of dosing in a Phase 1 first-in-human clinical study of RZ402, an investigational oral plasma kallikrein inhibitor (PKI), for the treatment of diabetic macular edema (DME).
-
Clinical Catch-Up: January 4-8
1/11/2021
The new year began with a fairly low level of clinical trial news. Here’s a look. -
Merus Announces Presentation of Phase 1 Clinical Data for MCLA-158 at the American Society of Clinical Oncology (ASCO) 2021 Gastrointestinal Cancers Symposium
1/11/2021
Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics™), today announced that clinical data from its Phase 1 dose escalation study of MCLA-158 will be presented in a poster session at the American Society of Clinical Oncology (ASCO) 2021 Gastrointestinal Cancers Symposium (ASCO G